Trinity Biotech plc (Nasdaq:TRIB), a leading developer and
manufacturer of diagnostic products for the point-of-care and
clinical laboratory markets, today announced results for the
quarter ended September 30, 2011.
Quarter 3 Results
Total revenues for Q3, 2011 were $19.8m which compares to $18.7m
in Q3, 2010, representing an increase of 6%.
Point-of-care revenues for Q3, 2011 decreased by 6% when
compared to Q3, 2010. This was attributable to lower HIV sales in
Africa, mainly due to timing factors. Consequently, it is expected
that this will be offset by correspondingly increased revenues in
Q4, 2011.
Clinical Laboratory revenues increased from $14.5m to $15.9m,
which represents an increase of 9% compared to Q3, 2010. However,
excluding Fitzgerald revenues, which fell by 6% in the quarter, the
increase in our core diabetes/infectious diseases revenues was
13%.
Revenues for Q3, 2011 by key product area were as follows:
|
|
|
|
|
2010 Quarter
3 |
2011 Quarter
3 |
Increase/
Decrease |
|
US$'000 |
US$'000 |
% |
Point-of-Care |
4,202 |
3,941 |
-6% |
|
|
|
|
Clinical Laboratory |
14,547 |
15,885 |
9% |
|
|
|
|
Total |
18,749 |
19,826 |
6% |
Gross profit for Q3, 2011 amounted to $10.3m, representing
a gross margin of 51.7% which compares favourably to the gross
margin of 50.6% for the same period in 2010. This continues the
trend of improving gross margins since the divestiture of the
coagulation product line in Q2, 2010.
Research and Development expenses increased from $0.8m to $0.9m,
an increase of 13.1%. Meanwhile, Selling, General and
Administrative (SG&A) expenses have decreased by 8.5% to $5.2m
compared to Q3, 2010. This is due to the elimination of costs
which were initially retained during the transition period
following the divestiture of the coagulation product line.
Operating profit for Q3, 2011 was $4.1m, and represents an
increase of over 25% when compared with Q3, 2010. Operating
margin at 20.7% remains above our target of 20% and represents a
significant improvement compared to the 17.4% reported in Q3,
2010.
Net financial income for Q3, 2011 was $0.5m which compares to
net financial income of $0.4m in Q3, 2010. This improvement is
attributable to a lower interest expense due to the repayment of
some minor elements of lease and other financing, in addition to
higher interest income being earned on increased cash balances.
The tax charge for Q3, 2011 was $0.7m which represents an
effective tax rate of 15.3%. This compares with an effective rate
of 6.6% in Q3, 2010, which was lower due to the utilisation of tax
losses forward.
Profit After Tax was $3.9m which is an increase of 12.2% over
Q3, 2010. Similarly, EPS for Q3, 2011 increased by 12.1% from 16.5
cents to 18.5 cents.
Free Cash Flows generated during the quarter were slightly over
$3m. This in turn was offset by $3m spent on share repurchases
and the payment of a scheduled deferred consideration payment of
$0.3m in relation to the acquisition of Phoenix Biotech. The
net result is that our cash position has remained broadly static at
$71.1m.
Share buyback
During the quarter, we repurchased 291,223 ADRs at an average
price of $10.28 as part of our share buyback program. The
total amount spent on repurchases during the quarter was just over
$3m.
Comments
Commenting on the results, Kevin Tansley, Chief Financial
Officer, said "We are very pleased with our results this quarter as
we are showing improvements in all of our key indicators. Revenues
have grown by 6% and profits and EPS are each up by over 12%.
This increase in profitability was achieved notwithstanding
the increase of over $500,000 in the tax charge this quarter when
compared to the particularly low effective tax rate in quarter 3,
2010. Meanwhile, our gross margin has increased to 51.7% and
our operating margin has continued to improve, reaching a new high
of 20.7%. We continue to generate strong cash flows, which in
this quarter were used to fund our on-going share buyback
program."
Ronan O'Caoimh, CEO, stated "We continue to deliver on our key
objectives of simultaneously growing revenues and profitability. We
are particularly pleased with the 13% organic revenue growth in our
key infectious diseases and diabetes business. This was
achieved before the impact of our new A1c instrument, Premier,
which has just been launched. Meanwhile, we are making
excellent progress on the development of our new point-of-care
products, the first of which will be submitted to the FDA for
approval later this year."
Forward-looking statements in this release are made pursuant to
the "safe harbor" provision of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties
including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States
Food and Drug Administration and other agencies, the impact of
competitive products, product development commercialisation and
technological difficulties, and other risks detailed in the
Company's periodic reports filed with the Securities and Exchange
Commission.
Trinity Biotech develops, acquires, manufactures and markets
diagnostic systems, including both reagents and instrumentation,
for the point-of-care and clinical laboratory segments of the
diagnostic market. The products are used to detect infectious
diseases and to quantify the level of Haemoglobin A1c and other
chemistry parameters in serum, plasma and whole blood. Trinity
Biotech sells direct in the United States, Germany, France and the
U.K. and through a network of international distributors and
strategic partners in over 75 countries worldwide. For further
information, please see the Company's website:
www.trinitybiotech.com.
The Trinity Biotech PLC logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10602
Trinity Biotech
plc |
Consolidated Income
Statements |
|
|
|
|
|
(US$000's except share data) |
Three Months Ended Sept 30,
2011 |
Three Months Ended Sept 30,
2010 |
Nine Months Ended Sept 30,
2011 |
Nine Months Ended Sept 30,
2010 |
|
(unaudited) |
(unaudited) |
(unaudited) |
(unaudited) |
|
|
|
|
|
Revenues |
19,826 |
18,749 |
57,935 |
70,388 |
|
|
|
|
|
Cost of sales |
(9,571) |
(9,262) |
(28,119) |
(36,215) |
|
|
|
|
|
Gross profit |
10,255 |
9,487 |
29,816 |
34,173 |
Gross profit % |
51.7% |
50.6% |
51.5% |
48.5% |
|
|
|
|
|
Other operating income |
191 |
651 |
721 |
1,234 |
|
|
|
|
|
Research & development expenses |
(857) |
(758) |
(2,344) |
(3,750) |
Selling, general and administrative
expenses |
(5,237) |
(5,721) |
(15,500) |
(20,426) |
Indirect share based payments |
(252) |
(392) |
(1,006) |
(779) |
|
|
|
|
|
Operating profit |
4,100 |
3,267 |
11,687 |
10,452 |
|
|
|
|
|
Non-recurring items |
-- |
(587) |
-- |
46,474 |
|
|
|
|
|
Financial income |
549 |
514 |
1,822 |
792 |
Financial expenses |
(3) |
(69) |
(10) |
(426) |
Net financial income |
546 |
445 |
1,812 |
366 |
|
|
|
|
|
Profit before tax |
4,646 |
3,125 |
13,499 |
57,292 |
|
|
|
|
|
Income tax expense on operating
activities |
(711) |
(206) |
(1,950) |
(888) |
Income tax credit on non-recurring items |
-- |
-- |
-- |
354 |
Profit for the
period |
3,935 |
2,919 |
11,549 |
56,758 |
Profit for the period (excluding
non-recurring items) |
3,935 |
3,506 |
11,549 |
9,930 |
|
|
|
|
|
Earnings per ADR (US cents) |
18.5 |
13.8 |
54.1 |
268.6 |
Earnings per ADR (US cents) – excluding
non-recurring items |
18.5 |
16.5 |
54.1 |
47.0 |
|
|
|
|
|
Diluted earnings per ADR (US cents) |
17.7 |
13.5 |
51.8 |
263.9 |
Diluted earnings per ADR (US cents) –
excluding non-recurring items |
17.7 |
16.2 |
51.8 |
46.2 |
|
|
|
|
|
Weighted average no. of ADRs used in
computing basic earnings per ADR |
21,297,539 |
21,183,785 |
21,345,527 |
21,127,858 |
|
|
|
|
|
The above financial statements
have been prepared in accordance with the principles of
International Financial Reporting Standards and the Company's
accounting policies but do not constitute an interim financial
report as defined in IAS 34 (Interim Financial
Reporting). |
Trinity
Biotech plc Consolidated Balance Sheets |
|
|
|
|
Sept 30,
2011 US$ '000
(unaudited) |
June 30,
2011 US$ '000
(unaudited) |
March 31,
2011 US$ '000
(unaudited) |
Dec 31,
2010 US$ '000
(audited) |
ASSETS |
|
|
|
|
Non-current assets |
|
|
|
|
Property, plant and equipment |
7,603 |
7,260 |
6,630 |
5,999 |
Goodwill and intangible assets |
43,515 |
41,799 |
40,267 |
37,248 |
Deferred tax assets |
3,950 |
4,158 |
4,385 |
4,680 |
Other assets |
509 |
534 |
11,729 |
11,623 |
Total non-current
assets |
55,577 |
53,751 |
63,011 |
59,550 |
|
|
|
|
|
Current assets |
|
|
|
|
Inventories |
19,478 |
18,971 |
18,636 |
17,576 |
Trade and other receivables |
23,172 |
23,686 |
24,078 |
25,529 |
Income tax receivable |
156 |
199 |
91 |
217 |
Cash and cash equivalents |
71,128 |
71,422 |
59,818 |
58,002 |
Total current assets |
113,934 |
114,278 |
102,623 |
101,324 |
|
|
|
|
|
TOTAL ASSETS |
169,511 |
168,029 |
165,634 |
160,874 |
|
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
|
Equity attributable to the equity
holders of the parent |
|
|
|
|
Share capital |
1,103 |
1,097 |
1,094 |
1,092 |
Share premium |
2,683 |
2,055 |
1,743 |
161,599 |
Accumulated surplus/(deficit) |
141,177 |
139,928 |
137,705 |
(25,412) |
Other reserves |
4,008 |
4,008 |
4,008 |
4,008 |
Total equity |
148,971 |
147,088 |
144,550 |
141,287 |
|
|
|
|
|
Current liabilities |
|
|
|
|
Interest-bearing loans and borrowings |
152 |
176 |
174 |
162 |
Income tax payable |
812 |
770 |
890 |
597 |
Trade and other payables |
11,411 |
12,153 |
12,680 |
11,447 |
Provisions |
50 |
50 |
50 |
50 |
Total current
liabilities |
12,425 |
13,149 |
13,794 |
12,256 |
|
|
|
|
|
Non-current liabilities |
|
|
|
|
Interest-bearing loans and borrowings |
-- |
34 |
74 |
111 |
Other payables |
16 |
62 |
52 |
30 |
Deferred tax liabilities |
8,099 |
7,696 |
7,164 |
7,190 |
Total non-current
liabilities |
8,115 |
7,792 |
7,290 |
7,331 |
|
|
|
|
|
TOTAL LIABILITIES |
20,540 |
20,941 |
21,084 |
19,587 |
|
|
|
|
|
TOTAL EQUITY AND
LIABILITIES |
169,511 |
168,029 |
165,634 |
160,874 |
|
The above financial
statements have been prepared in accordance with the principles of
International Financial Reporting Standards and the Company's
accounting policies but do not constitute an interim financial
report as defined in IAS 34 (Interim Financial Reporting). |
Trinity Biotech
plc |
Consolidated Statement
of Cash Flows |
|
|
|
|
|
(US$000's) |
Three Months Ended Sept 30,
2011 |
Three Months Ended Sept 30,
2010 |
Nine Months Ended Sept 30,
2011 |
Nine Months Ended Sept 30,
2010 |
|
(unaudited) |
(unaudited) |
(unaudited) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at
beginning of period |
71,422 |
50,042 |
58,002 |
6,078 |
|
|
|
|
|
Operating cash flows before changes in
working capital |
5,029 |
5,260 |
14,967 |
14,586 |
Changes in working capital |
(335) |
(332) |
(231) |
1,357 |
Cash generated from operations |
4,694 |
4,928 |
14,736 |
15,943 |
|
|
|
|
|
Net Interest and Income taxes
received/(paid) |
417 |
347 |
1,463 |
(230) |
|
|
|
|
|
Capital Expenditure & Financing
(net) |
(2,069) |
(1,515) |
(6,268) |
(4,950) |
|
|
|
|
|
Free cash flow |
3,042 |
3,760 |
9,931 |
10,763 |
|
|
|
|
|
Proceeds from sale of Coagulation product
line |
-- |
-- |
11,250 |
66,517 |
|
|
|
|
|
Cash paid to acquire Phoenix Bio-tech |
(333) |
-- |
(1,833) |
-- |
|
|
|
|
|
Repurchase of own company shares |
(3,003) |
-- |
(4,073) |
-- |
|
|
|
|
|
Dividend Payment |
-- |
-- |
(2,149) |
-- |
|
|
|
|
|
Repayment of bank debt |
-- |
-- |
-- |
(29,556) |
|
|
|
|
|
Cash and cash equivalents at end of
period |
71,128 |
53,802 |
71,128 |
53,802 |
|
|
|
|
|
|
|
|
|
|
The above financial statements
have been prepared in accordance with the principles of
International Financial Reporting Standards and the Company's
accounting policies but do not constitute an interim financial
report as defined in IAS 34 (Interim Financial Reporting). |
CONTACT: Trinity Biotech plc
Kevin Tansley
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com
Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2023 to Apr 2024